JP2020502179A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502179A5 JP2020502179A5 JP2019532806A JP2019532806A JP2020502179A5 JP 2020502179 A5 JP2020502179 A5 JP 2020502179A5 JP 2019532806 A JP2019532806 A JP 2019532806A JP 2019532806 A JP2019532806 A JP 2019532806A JP 2020502179 A5 JP2020502179 A5 JP 2020502179A5
- Authority
- JP
- Japan
- Prior art keywords
- allele
- hla
- tcdb
- snp
- drb1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022212848A JP2023055222A (ja) | 2016-12-14 | 2022-12-29 | クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー |
| JP2025002966A JP2025061120A (ja) | 2016-12-14 | 2025-01-08 | クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/109900 | 2016-12-14 | ||
| PCT/CN2016/109900 WO2018107388A1 (en) | 2016-12-14 | 2016-12-14 | Human genetic markers associated with response to treatments that target clostridium difficile toxin b |
| US201762508066P | 2017-05-18 | 2017-05-18 | |
| US62/508,066 | 2017-05-18 | ||
| PCT/US2017/064985 WO2018111662A1 (en) | 2016-12-14 | 2017-12-07 | Human genetic markers associated with response to treatments that target clostridium difficile toxin b |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022212848A Division JP2023055222A (ja) | 2016-12-14 | 2022-12-29 | クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020502179A JP2020502179A (ja) | 2020-01-23 |
| JP2020502179A5 true JP2020502179A5 (https=) | 2021-02-04 |
Family
ID=62559092
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532806A Pending JP2020502179A (ja) | 2016-12-14 | 2017-12-07 | クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー |
| JP2022212848A Pending JP2023055222A (ja) | 2016-12-14 | 2022-12-29 | クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー |
| JP2025002966A Ceased JP2025061120A (ja) | 2016-12-14 | 2025-01-08 | クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022212848A Pending JP2023055222A (ja) | 2016-12-14 | 2022-12-29 | クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー |
| JP2025002966A Ceased JP2025061120A (ja) | 2016-12-14 | 2025-01-08 | クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12071666B2 (https=) |
| EP (1) | EP3555303B1 (https=) |
| JP (3) | JP2020502179A (https=) |
| CN (1) | CN110088300A (https=) |
| AU (1) | AU2017375590A1 (https=) |
| BR (1) | BR112019012203A2 (https=) |
| MX (1) | MX2019007012A (https=) |
| RU (1) | RU2761249C2 (https=) |
| WO (1) | WO2018111662A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12071666B2 (en) * | 2016-12-14 | 2024-08-27 | Merck Sharp & Dohme Llc | Human genetic markers associated with response to treatments that target clostridium difficile toxin B |
| CN112481395B (zh) * | 2019-09-12 | 2024-10-18 | 深圳华大生命科学研究院 | 艰难梭菌耐药/低敏感进化分支snp标记及菌株类别鉴定方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA2044591C (en) | 1989-02-13 | 2002-08-13 | James Langham Dale | Detection of a nucleic acid sequence or a change therein |
| US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5302509A (en) | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| ATE198358T1 (de) | 1992-04-27 | 2001-01-15 | Dartmouth College | Detektion von gensequenzen in biologischen flüssigkeiten |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| IL108159A (en) | 1993-12-23 | 1998-02-08 | Orgenics Ltd | Apparatus for separation, concentration and detection of target molecules in liquid sample |
| EP0754240B1 (en) | 1994-02-07 | 2003-08-20 | Beckman Coulter, Inc. | Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis |
| US6300063B1 (en) | 1995-11-29 | 2001-10-09 | Affymetrix, Inc. | Polymorphism detection |
| AU710425B2 (en) | 1995-12-18 | 1999-09-23 | Washington University | Method for nucleic acid analysis using fluorescence resonance energy transfer |
| ES2215241T3 (es) | 1996-11-06 | 2004-10-01 | Sequenom, Inc. | Procedimiento de espectrometria de masa. |
| DE19782097T1 (de) | 1996-11-06 | 1999-10-14 | Sequenom Inc | Zusammensetzungen und Verfahren zur Immobilisierung von Nucleinsäuren an feste Träger |
| JP2010522560A (ja) * | 2007-03-27 | 2010-07-08 | デューク ユニバーシティ | Ｈｉｖ疾患制限に関連する遺伝的変異体 |
| US20100035265A1 (en) | 2008-07-18 | 2010-02-11 | Aris Floratos | Biomarkers for Drug-Induced Liver Injury |
| WO2010050829A1 (en) | 2008-10-31 | 2010-05-06 | Vialactia Biosciences (Nz) Limited | Marker assisted selection of a mammalian subject for desired immunoglobulin phenotype |
| PE20120056A1 (es) | 2009-02-24 | 2012-02-05 | Merck Sharp & Dohme | Derivados de indol como antagonistas del receptor crth2 |
| HUE029098T2 (en) * | 2009-08-21 | 2017-02-28 | Novartis Ag | To treat lapatinib cancer |
| SG10201701055WA (en) * | 2011-09-16 | 2017-03-30 | Ucb Pharma Sa | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
| AU2012328524B2 (en) * | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| US10280470B2 (en) * | 2013-01-11 | 2019-05-07 | Baylor College Of Medicine | Biomarkers of recurrent Clostridium difficile infection |
| EP3004386B1 (en) * | 2013-05-29 | 2019-08-07 | Immunexpress Pty Ltd | Microbial markers and uses therefor |
| US9181632B1 (en) * | 2013-09-09 | 2015-11-10 | Merck Sharp & Dohme Corp. | C.difficile toxin B CROP domain peptides, antibodies and complexes thereof |
| CN103665141B (zh) * | 2013-12-31 | 2015-09-16 | 北京大学 | 与艰难梭菌细胞毒素b相互作用的蛋白 |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| US12071666B2 (en) * | 2016-12-14 | 2024-08-27 | Merck Sharp & Dohme Llc | Human genetic markers associated with response to treatments that target clostridium difficile toxin B |
| WO2018107388A1 (en) | 2016-12-14 | 2018-06-21 | Merck Sharp & Dohme Corp. | Human genetic markers associated with response to treatments that target clostridium difficile toxin b |
-
2017
- 2017-12-07 US US16/468,982 patent/US12071666B2/en active Active
- 2017-12-07 CN CN201780077861.1A patent/CN110088300A/zh active Pending
- 2017-12-07 JP JP2019532806A patent/JP2020502179A/ja active Pending
- 2017-12-07 MX MX2019007012A patent/MX2019007012A/es unknown
- 2017-12-07 RU RU2019122099A patent/RU2761249C2/ru active
- 2017-12-07 EP EP17881986.8A patent/EP3555303B1/en active Active
- 2017-12-07 BR BR112019012203-6A patent/BR112019012203A2/pt active Search and Examination
- 2017-12-07 WO PCT/US2017/064985 patent/WO2018111662A1/en not_active Ceased
- 2017-12-07 AU AU2017375590A patent/AU2017375590A1/en not_active Abandoned
-
2022
- 2022-12-29 JP JP2022212848A patent/JP2023055222A/ja active Pending
-
2025
- 2025-01-08 JP JP2025002966A patent/JP2025061120A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Atreya et al. | Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to anti-TNF? | |
| Farago et al. | Combination olaparib and temozolomide in relapsed small-cell lung cancer | |
| Lichtenstein et al. | ACG clinical guideline: management of Crohn's disease in adults | |
| Atreya et al. | Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease | |
| Lim et al. | The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use | |
| Hoang et al. | Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease | |
| Uniken Venema et al. | The genetic background of inflammatory bowel disease: from correlation to causality | |
| JP2021072777A (ja) | ヒトミクロビオームおよびその成分の分析のための無細胞核酸 | |
| Scheper et al. | Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate‐associated osteonecrosis | |
| TW201938796A (zh) | 使用atr抑制劑治療癌症之方法 | |
| JP2015504430A (ja) | Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 | |
| Dai et al. | The treatment of macrolide‐resistant Mycoplasma pneumoniae pneumonia in children | |
| Sabzevary-Ghahfarokhi et al. | The expression analysis of Fra-1 gene and IL-11 protein in Iranian patients with ulcerative colitis | |
| WO2025085928A1 (en) | Methods of treating a patient with an inflammatory bowel disease | |
| EP2622101A2 (en) | Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors | |
| JP2020502179A5 (https=) | ||
| Allami et al. | Genetic Association of Angiotensin-converting enzyme 2 ACE-2 (rs2285666) Polymorphism with the Susceptibility of COVID-19 Disease in Iraqi Patients. | |
| WO2019178215A1 (en) | Methods and compositions for treating, prognosing, and diagnosing esophageal cancer | |
| Sanders et al. | Multiple recurrent de novo copy number variations (CNVs), including duplications of the 7q11. 23 Williams-Beuren syndrome region, are strongly associated with autism | |
| Xiao et al. | Integrative blood-derived epigenetic and transcriptomic analysis reveals the potential regulatory role of DNA methylation in ankylosing spondylitis | |
| RU2019122099A (ru) | Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile | |
| KR20250152080A (ko) | 궤양성 결장염에서의 유전자의 조절 및 그의 용도 | |
| CN112029847B (zh) | 检测hla-a*30:01等位基因的物质在评价左氧氟沙星所致重症药疹风险中的应用 | |
| Fatima et al. | Detection of methicillin resistant staphylococcus aureus using mec a, ribotyping and antibiogram profile of Pakistani clinical isolates | |
| TW201343176A (zh) | 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法 |